Astrazeneca Pharma India Ltd (ASTRAZEN) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Small Cap

Astrazeneca Pharma I Share Price

8,740.10 143.95 1.67%
as on 06-Mar'26 16:59

DeciZen - make an informed investing decision on Astrazeneca Pharma I

Based on:

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Astrazeneca Pharma India stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
108.77
Market Cap:
21,850.3 Cr.
52-wk low:
6,501.6
52-wk high:
10,653.1

Is Astrazeneca Pharma India Ltd an attractive stock to invest in?

1. Is Astrazeneca Pharma India Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Astrazeneca Pharma India Ltd is a good quality company.

2. Is Astrazeneca Pharma India Ltd undervalued or overvalued?

The key valuation ratios of Astrazeneca Pharma India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Astrazeneca Pharma India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Astrazeneca Pharma India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Astrazeneca Pharma I:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astrazeneca Pharma India Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 3.8%18.7%18.7%26.5%34.6%31.2%17.4%24.5%33.9%21.3%-
Value Creation
Index
-0.70.30.30.91.61.30.30.81.50.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5645445717288328148061,0031,2961,7162,177
Sales YoY Gr.--3.6%5%27.6%14.2%-2.2%-1%24.5%29.2%32.5%-
Adj EPS 2.25.910.521.628.936.923.950.260.173.480.4
YoY Gr.-171.6%76.5%106.5%34.1%27.4%-35.2%110.1%19.8%22.1%-
BVPS (₹) 62.488.597.9119.5145.1181.8203.8234.5283.5305.3332.6
Adj Net
Profit
5.514.826.15472.392.259.7126150184201
Cash Flow from Ops. 5738.18.85587.410510158.327.965.4-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.2%15.6%28.7%32.5%
Adj EPS 47.8%20.5%45.4%22.1%
BVPS19.3%16%14.4%7.7%
Share Price 21.9% 20.5% 37.5% 16.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
3.67.811.119.721.722.512.322.823.124.825.2
Op. Profit
Mgn %
36.98.29.814.616.710.716.514.314.813.2
Net Profit
Mgn %
12.74.67.48.711.37.412.511.610.79.2
Debt to
Equity
0000000000-
Working Cap
Days
167185216176167193200185179206121
Cash Conv.
Cycle
171112-0-2-164235057

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 25.20%

Sales growth is growing at healthy rate in last 3 years 28.67%

Net Profit is growing at healthy rate in last 3 years 45.38%

Sales growth is good in last 4 quarters at 34.28%

No data to display

Latest Financials - Astrazeneca Pharma India Ltd.

Standalone Consolidated
TTM EPS (₹) 80.4 -
TTM Sales (₹ Cr.) 2,177 -
BVPS (₹.) 332.6 -
Reserves (₹ Cr.) 827 -
P/BV 26.28 -
PE 108.77 -
From the Market
52 Week Low / High (₹) 6501.60 / 10653.05
All Time Low / High (₹) 9.00 / 10653.05
Market Cap (₹ Cr.) 21,850
Equity (₹ Cr.) 5
Face Value (₹) 2
Industry PE 42.2

Management X-Ray of Astrazeneca Pharma I:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Astrazeneca Pharma I - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Astrazeneca Pharma I

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales5645445717288328148061,0031,2961,716
Operating Expenses 5475075256577116787198381,1111,462
Manufacturing Costs33445958495765829454
Material Costs195171178227300287305355590958
Employee Cost 169162150197217220230259241257
Other Costs 150129137175146115119142185193
Operating Profit 1637467112113586165184254
Operating Profit Margin (%) 2.9%6.8%8.1%9.8%14.5%16.7%10.7%16.5%14.2%14.8%
Other Income 7141216131315263541
Interest 0000111111
Depreciation 17161515192017161540
Exceptional Items 0000000-4016-97
Profit Before Tax 636447311412783134220156
Tax 1151818423421355841
Profit After Tax 520265472936299162116
PAT Margin (%) 0.9%3.7%4.5%7.5%8.7%11.5%7.6%9.9%12.5%6.7%
Adjusted EPS (₹)2.18.010.421.828.937.324.639.764.646.3
Dividend Payout Ratio (%)0%0%0%0%3%5%41%40%37%69%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 156221245299363455509586709763
Share Capital 5555555555
Reserves 151216240294358450504581704758
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables9588127168210178190228197456
Others Liabilities 178205203124203241277328372618
Total Liabilities 4295145755917768749771,1421,2771,838

Fixed Assets

Gross Block204103106120133160169179187218
Accumulated Depreciation106163045617994110120153
Net Fixed Assets 97877575728174696764
CWIP 65472442100
Investments 0000000000
Inventories7758113118165160140190228549
Trade Receivables83435580838586108153185
Cash Equivalents flag 77116126173253352448500506537
Others Assets 89206203138179192226274323503
Total Assets 4295145755917768749771,1421,2771,838

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 573895587105101582865
PBT 636447311412783134220156
Adjustment 121538101410-5-776
Changes in Working Capital 42-0-3410-3-433-30-128-103
Tax Paid -3-12-4-35-34-33-25-41-56-64
Cash Flow From Investing Activity -40-94-1711735182231
Capex -9-5-6-18-14-5-6-5-10-1
Net Investments 00-1112-1691690000
Others 5681112911233232
Cash Flow From Financing Activity -1000-6-9-9-24-44-66
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -0000-1-1-1-1-1-1
Dividend Paid 0000-3-5-5-20-40-60
Others -0000-3-3-4-4-4-4
Net Cash Flow 5338-159-902699652531

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)3.4310.6311.1220.0321.8322.8312.7818.1324.9515.73
ROCE (%)3.7618.7418.6526.5334.6131.2417.3624.4933.9421.29
Asset Turnover Ratio1.361.161.051.251.220.990.870.951.081.11
PAT to CFO Conversion(x)11.41.90.351.021.211.131.630.590.170.56
Working Capital Days
Receivable Days40423134363839353736
Inventory Days52455558627368605982
Payable Days193194220238230247220215131124

Astrazeneca Pharma India Ltd Stock News

Astrazeneca Pharma India Ltd FAQs

The current trading price of Astrazeneca Pharma I on 06-Mar-2026 16:59 is ₹8,740.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 05-Mar-2026 the market cap of Astrazeneca Pharma I stood at ₹21,850.3.
The latest P/E ratio of Astrazeneca Pharma I as of 05-Mar-2026 is 108.8.
The latest P/B ratio of Astrazeneca Pharma I as of 05-Mar-2026 is 26.28.
The 52-week high of Astrazeneca Pharma I is ₹10,653.1 and the 52-week low is ₹6,501.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astrazeneca Pharma I is ₹2,177 ( Cr.) .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India (AZPIL), incorporated on July 11, 1979, is a global, science-led, patient-focused pharmaceutical company. The company is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom. The company is dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. The company’s focus areas in India include BioPharmaceuticals, Oncology, and Rare Diseases, which are pivotal to its Growth Through Innovation strategy.

The company operates with purpose and integrity, using science, innovation, and global reach to deliver life-changing medicines. It is committed to equitable access, healthier communities, and environmental responsibility across its value chain. By embedding sustainability at its core and following the science, the company strives to improve health outcomes and create lasting value for patients, society, and the planet.

Rated as one of the finest in South East Asia, AstraZeneca’s Indian manufacturing facility has a sophisticated production facility designed to meet the most stringent international standards, conforming to WHO cGMP (current Good Manufacturing Practices) norms. The facility is an ISO 14001 certified company and has a full-fledged environment management system in place.

The company engages in execution of clinical studies to generate high quality data eligible for submissions to regulatory agencies across the world aimed at developing life altering medical products. Guided by the values & processes of AstraZeneca, international guidelines & local regulatory framework the team collaborates with top-notch healthcare practitioners and medical institutes to bring AstraZeneca’s medicines as quickly, safely and efficiently as possible.

Business area of the company

AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The company engages in execution of clinical studies to generate high quality data eligible for submissions to regulatory agencies across the world aimed at developing life altering medical products.

Core Therapy Areas

  • Oncology
  • BioPharmaceuticals
  • Rare Disease

Milestones and achievements

  • 1979: Formation of AstraIDL, promoted by Astra Pharmaceuticals AB Sweden and IDL Chemicals Hyderabad.
  • 1982: Astra-IDL listed on the Bombay Stock Exchange (BSE) - 5.6 times oversubscription.
  • 1982: Foundation stone of the Yelahanka site laid by the Prime Minister of Sweden.
  • 1988: Started maternal health product division.
  • 1989: Launched Restomycin, Bromenyl, Febrafen and Prostodin.
  • 1996: Inauguration of R&D Centre in Bengaluru.
  • 1998: Astra IDL touched its first Rs 100 crore mark with a revenue of Rs 102.47 crore.
  • 1999: AstraZeneca formed by the global merger of Astra and Zeneca.
  • 2001: AstraZeneca announced it had completed a transaction to buy a controlling stake in the joint venture company Astra-IDL and renamed it AstraZeneca Pharma India Ltd.
  • 2001: Introduction of Seloken XL. Partnership with Bristol-Myers Squibb (BMS).
  • 2003: Launch of Seloken XL.
  • 2010: Launch of Young Health Programme (YHP) in India.
  • 2011: AstraZeneca crosses Rs 500 crore turnover mark.
  • 2012: Launch of Brilinta.
  • 2014: Move of commercial operations and clinical operations to Manyata Tech Park, Bengaluru.
  • 2014: Launch of new tablet production facility.
  • 2014: Launch of Global Technology Chennai (GTC).
  • 2015: Launch of Forxiga.
  • 2016: AZ IT’s three-year IT Transformation Journey completed successfully in 2016.
  • 2017: Launch of Tagrisso.
  • 2017: Launch of GBS Global Commercial Operations India.
  • 2018: Launch of the first Metabolic Centre of Excellence.
  • 2019: 40th anniversary of AstraZeneca and launch of India- Sweden Healthcare Innovation Centre.
  • 2021: AstraZeneca global’s COVID-19 vaccine saved more than six million lives worldwide. Around 3 billion vaccine doses supplied worldwide, with significant contributions to lowand middle-income countries.
  • 2021: Establishing and expanding the CDI footprint in India: launched a clinical data and insights division in India to further strengthen its global presence, and for the management of data-related aspects of its clinical trials.
  • 2022: Rebranded Global Technology Centre to Global Innovation Technology Centre (GITC).
  • 2022: Established Clinical Regulatory Writing (CReW) to drive strategic medical writing excellence across R&D.
  • 2023: Launched its India Bold Ambition aligning with its Growth Through Innovation Strategy.
  • 2023: MoU with Government of Karnataka to deploy Artificial Intelligence (AI) based Lung Cancer screening technology in 19 district hospitals.
  • 2023: Signed MoU with Roche Diagnostics India to improve diagnostics for breast cancer patients.
  • 2023: Launched the global AZ Forest initiative in India in the state of Meghalaya.
  • 2023: Expanded portfolio with Rare Disease Business Unit (BU) with the launch of Selumetinib.
  • 2023: Expanded its R&D division in Bengaluru.
  • 2024: MoU with Government of Goa to accelerate the detection of lung cancer in the state.
  • 2024: AstraZeneca celebrates 45 years in India. Continued focus on accelerating the delivery of life-changing medicines and operating sustainably.
  • 2024: AstraZeneca celebrates 10 years of GITC, India.
  • 2024: AstraZeneca Pharma India and Mankind Pharma entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.
  • 2025: AstraZeneca Pharma India (AstraZeneca) entered into distribution services agreement with Sun Pharmaceutical Industries (Sun Pharma) for the distribution of Sodium Zirconium Cyclosilicate (SZC) powder for oral suspension 5 g in India.
  • 2026: AstraZeneca Pharma India received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Brand Name: Imfinzi) for an additional indication.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×